CSPI seeks fed block on Promensil ads, labels
This article was originally published in The Tan Sheet
Executive Summary
The Center for Science in the Public Interest asks FDA and the Federal Trade Commission to halt Natrol's advertising and health claims for its red clover dietary supplement Promensil, indicated for the treatment of hot flashes, night sweats and mood swings. In a Sept. 12 letter to the agencies, CSPI said Natrol's claims that Promensil is "the only supplement proven to reduce menopause symptoms" and that it promotes "heart health" are deceptive and misleading. CSPI says its own analysis of the scientific research to support the efficacy of the supplement showed the data did not support Natrol's claims. The letter requests the Chatsworth, Calif.-based firm reimburse consumers, pay a penalty and run corrective advertising to "set the record straight"...